Heat Biologics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
09 September 2021 - 10:30PM
Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage
biopharmaceutical company focused on developing first-in-class
therapies to modulate the immune system, today announced that Jeff
Wolf, Chief Executive Officer of Heat Biologics, will be presenting
at the H.C. Wainwright 23rd Annual Global Investment Conference
being held virtually between September 13-15, 2021.
Heat Biologics' presentation will be available
on-demand to registered attendees via the conference platform
beginning Monday, September 13, 2021 at 7:00 AM Eastern Time.
The webcast can be accessed here and on the
investor relations section of Heat Biologics' website at
https://ir.heatbio.com/. Management will also be participating in
one-on-one meetings with qualified members of the investor
community throughout the conference.
About Heat Biologics, Inc.Heat
Biologics is a biopharmaceutical company focused on developing
first-in-class therapies to modulate the immune system. Heat’s gp96
platform is designed to activate immune responses against cancer or
infectious diseases. The Company has multiple product candidates in
development leveraging the gp96 platform, including HS-110, which
has completed enrollment in a Phase 2 trial, various infectious
disease/biological threat programs in preclinical development and a
pipeline of proprietary immunomodulatory antibodies and cell-based
therapies, including PTX-35 and HS-130 in Phase 1 clinical
trials.
For more information, please
visit: www.heatbio.com, and also follow us
on Twitter.
Media and Investor Relations
ContactDavid Waldman+1 919 289
4017investorrelations@heatbio.com
Heat Biologics (NASDAQ:HTBX)
Historical Stock Chart
From Sep 2024 to Oct 2024
Heat Biologics (NASDAQ:HTBX)
Historical Stock Chart
From Oct 2023 to Oct 2024
Real-Time news about Heat Biologics Inc (NASDAQ): 0 recent articles
More News Articles